Literature DB >> 6299537

Selective effect of Rous sarcoma virus src gene expression on contractile protein synthesis in chick embryo myotubes.

C M West, D Boettiger.   

Abstract

Myogenic precursor cells were infected with a temperature-sensitive mutant of Rous sarcoma virus and maintained at the permissive temperature for transformation. Following subculture, a population of cells was produced which failed to differentiate at the permissive temperature but produced a high proportion of myotubes in sister cultures shifted to the nonpermissive temperature. The myotube-containing cultures were further enriched for this cell type by the addition of 1-beta-D-arabinofuranosylcytosine to kill replicating mononucleated cells. This myotube population was suitable for testing the effect of viral-transforming gene expression in a postmitotic, terminally differentiated cell which expresses relatively low levels of the cellular homologue of the viral-transforming gene and is resistant to infection by the virus. The consequence of shifting these Rous sarcoma virus-infected myotube cultures to the permissive temperature was assessed in terms of protein synthesis. The total rate of incorporation of exogenous radioactive leucine, supplied at a concentration which saturated the intracellular pool, was similar between cultures held at the two temperatures, suggesting that the absolute rate of total protein synthesis was not affected by expression of viral-transforming gene. In contrast, the rate of synthesis of eight proteins the expression of which is specific for myotubes was suppressed reversibly. The rate of synthesis of five other proteins which are not selectively concentrated in myotubes was either unaffected or stimulated. Thus. the expression of viral-transforming gene in myotubes leads to differential effects on developmentally regulated proteins without inducing several properties of the transformed state classically observed for fibroblastic cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299537

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Transcription of muscle-specific genes is repressed by reactivation of pp60v-src in postmitotic quail myotubes.

Authors:  G Falcone; S Alemà; F Tatò
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

Review 2.  Control of myogenic differentiation by cellular oncogenes.

Authors:  M D Schneider; E N Olson
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

3.  Distinctive effects of the viral oncogenes myc, erb, fps, and src on the differentiation program of quail myogenic cells.

Authors:  G Falcone; F Tatò; S Alemà
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  myc and src oncogenes have complementary effects on cell proliferation and expression of specific extracellular matrix components in definitive chondroblasts.

Authors:  S Alema; F Tato; D Boettiger
Journal:  Mol Cell Biol       Date:  1985-03       Impact factor: 4.272

5.  Crystallin gene expression and lentoid body formation in quail embryo neuroretina cultures transformed by the oncogenic retrovirus Mill Hill 2 or Rous sarcoma virus.

Authors:  L Simonneau; P Crisanti; A M Lorinet; F Alliot; Y Courtois; G Calothy; B Pessac
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

6.  Transformation of avian myogenic cultures with myelocytomatosis virus strain 29.

Authors:  Christopher M West
Journal:  Wilehm Roux Arch Dev Biol       Date:  1984-01

7.  Role of cell division in differentiation of myoblasts infected with a temperature-sensitive mutant of Rous sarcoma virus.

Authors:  G Falcone; D Boettiger; S Alemà; F Tatò
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

8.  A molecular defect in virally transformed muscle cells that cannot cluster acetylcholine receptors.

Authors:  D T Anthony; R J Jacobs-Cohen; G Marazzi; L L Rubin
Journal:  J Cell Biol       Date:  1988-05       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.